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To explore racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer.
Methods
The National Cancer Database was queried to identify women with stage 1 to 3 breast cancer diagnosed in 2010 and 2011. Chemotherapy use and rate of pathologic complete response (pCR) was determined for various racial/ethnic groups.
INTRODUCTION
Racial disparities in breast cancer incidence, treatment, and survival have been well described. [1] [2] [3] Data from the SEER Registry demonstrate that non-Hispanic white women are more likely to be given a diagnosis of breast cancer, but African American women are more likely to die as a result of the disease. 4, 5 In addition, African American women are more likely to receive a diagnosis at a younger age and to present with larger tumors and estrogen receptor (ER)-negative disease than nonHispanic white women. These differences are multifactorial and related to differences not only in tumor biology but also in screening practices, access to care, and overall socioeconomic status.
Despite these disparities in incidence and treatment, population-based data on differences in the use of and response to neoadjuvant chemotherapy are sparse. Neoadjuvant chemotherapy has several potential benefits, including initiation of systemic therapy without delay for surgery in patients with locally advanced and/or node-positive disease, consideration of select patients for additional systemic therapy and participation in clinical trials according to the in-breast response, increase in the number of women eligible for breast conservation by downsizing larger tumors, 6 and provision of prognostic information about survival.
We previously used data from the National Cancer Database (NCDB) to demonstrate that the use of neoadjuvant chemotherapy for patients with breast cancer increased from 13.9% in 2006 to 20.5% in 2011. 7 In 2010, the NCDB included a new variable, documentation of pathologic complete response (pCR) to neoadjuvant chemotherapy, which has been shown to be an important prognostic indicator. 8 Strong correlations have been described between pCR and improved outcomes in patients with aggressive breast cancer subtypes, including triple-negative tumors and human epidermal growth factor receptor 2 (HER2)-positive tumors, which tend to occur more commonly in nonwhite women. The purpose of this study was to explore racial differences in the use of neoadjuvant chemotherapy and rates of pCR.
METHODS
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society and contains approximately 80% of the cancer cases in the United States. After approval by the NCDB, patient deidentified data were downloaded from the Web site in January 2014 and analyzed in this study.
Study Population
The NCDB was queried to identify women with invasive stage 1 to 3 breast cancer diagnosed in 2010 and 2011 whose race and ethnicity were known and who had data that allowed determination of whether they received chemotherapy. Within the fields for race and ethnicity, a new variable was constructed to define non-Hispanic white, non-Hispanic black, non-Hispanic Asian/Pacific Islander, and Hispanic women. American Indian, Aleutian, or Eskimo women were excluded due to small numbers in these subpopulations.
Treatment Received
All 278,815 patients included in this study had information on whether chemotherapy was given. Of these, 127,417 (46%) received chemotherapy. A subset of patients also received endocrine therapy. To determine the temporal relationship between surgery and systemic therapy, an NCDB variable was used to indicate the sequence of systemic treatment. This variable was available for 122,067 of the 127,417 patients who received chemotherapy; of these, 27,720 (22.7%) received neoadjuvant therapy. To distinguish between neoadjuvant endocrine therapy or neoadjuvant radiation therapy, other variables were used to determine the time interval between diagnosis and chemotherapy, diagnosis and endocrine therapy, diagnosis and radiation therapy, and diagnosis and surgery. On the basis of these variables, 621 patients were excluded who may have had neoadjuvant endocrine or radiation therapy followed bypostsurgical chemotherapy. This left 27,300 (22.5%) of 121,446 who were known to have had neoadjuvant chemotherapy. Overall, these timing variables confirmed that the sequence variable was internally consistent.
Response to Chemotherapy
The variable in the NCDB that categorized the response to neoadjuvant chemotherapy was available for 17,970 of the 27,300 patients who received neoadjuvant chemotherapy. The outcome used, pCR, was defined as no remaining invasive cancer in either the breast or the axillary lymph nodes.
Other Variables
A new variable, molecular type, was constructed from combinations of the NCDB variables for ER, progesterone receptor (PR), and HER2. The four types were: ER/PR+, Her22 (ER or PR positive and HER2 negative); ER/PR+, HER2+ (ER or PR positive and HER2 positive); ER/PR2, HER2+ (ER and PR negative and HER2 positive); and ER/PR2, HER22 (ER, PR, and HER2 negative). The NCDB variable for HER2 was based on both information from immunochemistry and fluorescent in situ hybridization. Data on molecular type was missing for 30,617 (11.0%) patients, predominately due to missing data for HER2. Clinical T and N stage were used because they often are the basis for the determination of chemotherapy sequence. Data for clinical T stage and N stage were missing for 13.5% and 10.3%, respectively.
Statistical Analysis
Statistical analysis was performed with SPSS version 22 software (IBM, Chicago, IL). Bivariate and multivariate comparisons were performed with x 2 tests and logistic regression models to determine factors that contribute to receipt of chemotherapy and likelihood of pCR. Statistical tests were two-sided, and P , .05 was considered significant.
RESULTS
There were 278,815 patients in the NCDB with known race and ethnicity who met the study inclusion criteria. Patient and tumor characteristics for this group are presented in Table 1 . Non-Hispanic white women had higher rates of the ER/PR+, HER22 disease type, smaller tumor size, less nodal involvement, well-differentiated tumors, and older age at diagnosis compared with other racial groups. NonHispanic black women had the highest rates of triple-negative disease, and Hispanic women presented with the highest proportion of women age 30 or younger compared with other racial groups (P ,.001). NonHispanic white women were more likely to have Medicare insurance and to receive treatment from a comprehensive community cancer program (P , .001). Black and Hispanic women were more likely to have no insurance or Medicaid and to have a low level of income and education. Asian women were more likely than other groups to have a high level of education and had the highest income levels (P , .001).
Forty-six percent of patients (n = 127,417) received chemotherapy either with or without hormone therapy. Table 2 describes the univariable analyses with respect to (1) the receipt of chemotherapy, (2) the timing of chemotherapy, and (3) the achievement of pCR by patient demographics and tumor characteristics. Of 121,446 patients for whom the timing of chemotherapy was known, nearly one quarter (27,300 [23%]) received neoadjuvant chemotherapy. Women with HER2-positive tumors, with triple-negative breast cancer, and with lymph node-positive disease were more likely to receive neoadjuvant chemotherapy. Young age and larger tumor size were also associated with receipt of neoadjuvant chemotherapy. Overall, non-Hispanic black women were more likely than other racial groups to receive any systemic chemotherapy, whereas Hispanic women were most likely to receive neoadjuvant chemotherapy (P , .001 for both). Receipt and timing of chemotherapy were also related to socioeconomic variables. Uninsured women and those in the lowest income and education brackets were more likely than other groups to receive chemotherapy and to receive it before surgery, whereas Charlson/ Deyo comorbidity score was inversely related to receipt of chemotherapy regardless of timing. Table 3 shows various multiple regression models for receipt and timing of chemotherapy and achieving pCR. In unadjusted analysis, non-Hispanic black women were almost twice as likely as white women to receive chemotherapy (odds ratio [OR], 1.90; 95% CI, 1.86 to 1.95), and Hispanic women were most likely to receive neoadjuvant chemotherapy (OR, 1.58; 95% CI, 1.50 to 1.66). When adjusted for the other biologic and socioeconomic variables, there was no difference by race in the overall receipt of chemotherapy, but non-Hispanic black and Hispanic women were still slightly more likely to receive neoadjuvant chemotherapy.
Of 17,970 patients in whom the outcome after neoadjuvant chemotherapy was known, 5,944 (33%) had a pCR. In univariable analysis of the entire group, no difference was found in the percentage of women in each racial group who had a pCR (Table 2) . However, when stratified by molecular type, there were differences in pCR by race. Compared with white women, non-Hispanic black women, but not Hispanic or Asian women, had significantly lower rates of pCR for triple-negative tumors and HER2-overexpressing tumors (Table 4) . After adjusting for age, clinical T stage, clinical N stage, histology, grade, and molecular type, non-Hispanic black women were less likely than white women to demonstrate a pCR (OR, 0.84; 95% CI, 0.76 to 0.91), and this difference persisted even when adjusted for all the socioeconomic and comorbidity variables in the database (Table 3) .
To investigate whether treatment delays and/or more erratic chemotherapy administration may have affected the pCR rate, we considered the median duration of time from diagnosis to start of neoadjuvant chemotherapy and diagnosis to surgery by race. The difference (representing the length of time on chemotherapy plus waiting time for surgery) was also calculated. On average, non-Hispanic black patients had a longer time than white patients from diagnosis to the start of neoadjuvant chemotherapy (41.3 v 32.7 days, respectively; P , .001) and a longer time between the start of neoadjuvant chemotherapy to surgery (194.8 v 179.2 days, respectively; P , .001). This difference was even more pronounced among Hispanic patients, who waited 43.1 days on average to the start of neoadjuvant chemotherapy and 198.0 days to surgery (P ,.001 compared with white patients). The difference was 146.4 days for white patients, 153.5 days for black patients, and 155.0 days for Hispanic patients, which suggests differences in social and other factors affecting treatment. Non-Hispanic black patients also had a greater standard deviation for this difference (51.9 v 44.6 and 49.3 for white and Hispanic patients, respectively), which suggests that this group is quite heterogeneous.
DISCUSSION
We found that chemotherapy, and neoadjuvant chemotherapy in particular, is given more frequently to non-Hispanic black, Hispanic, and Asian women compared with non-Hispanic white women. Although this finding is largely explained by more advanced stage, higher grade tumors, and a greater proportion of triple-negative and HER2-positive tumors in these women, non-Hispanic black patients have a slightly lower likelihood of pCR after neoadjuvant chemotherapy than white patients.
Early trials describing the use of neoadjuvant chemotherapy in patients with locally advanced breast cancer demonstrated clinically Table 3 . Associations Among Race, Receipt of any Chemotherapy, Receipt of Neoadjuvant Chemotherapy, and Achievement of pCR significant decreases in tumor volume. 9 On the basis of these findings and the hypothesis that earlier initiation of chemotherapy improves overall survival for patients with early stage breast cancer, several randomized clinical trials compared the same chemotherapeutic agents given in the neoadjuvant versus the adjuvant setting. Each of the nine randomized trials and a meta-analysis published in 2005 demonstrated no difference in overall survival between neoadjuvant and adjuvant chemotherapy. 10 Nonetheless, several advantages to giving neoadjuvant chemotherapy exist, including an increase in the number of women eligible for breast conservation by downsizing larger tumors 6 ; smaller surgical excision volumes, even among women who are initially candidates for breast conservation 11 ; and provision of prognostic information that may influence subsequent treatment.
Although racial disparities in breast cancer treatment have been well documented, population-based data with regard to the use of and response to neoadjuvant chemotherapy by race are sparse. The current study used a large national population treated in 2010 and 2011 and shows that non-Hispanic black, Asian, and Hispanic women were more likely to receive any chemotherapy, and neoadjuvant chemotherapy in particular, than non-Hispanic white women. The finding that non-Hispanic white women were least likely to receive neoadjuvant chemotherapy may reflect that this group demonstrates the highest incidence of the ER/PR+, HER22 breast cancer type. Hispanic women were most likely to receive neoadjuvant chemotherapy; this group also had the highest percentage of women with breast cancer age 40 and younger. After adjusting for patient age, tumor stage, histology, grade, molecular type, comorbidity index, and indicators of socioeconomic status, there was no significant difference in the receipt of chemotherapy among the racial/ethnic groups, but there was still a slightly higher use of neoadjuvant chemotherapy among non-Hispanic black and Hispanic women.
In the current study, black women but not Asian or Hispanic women had a notably lower rate of pCR than white women for triple-negative and HER2-positive tumors. The reasons for this finding are not clear. Several studies [12] [13] [14] [15] have looked at this question, and most concluded that no difference in pCR rate exists by race. Many of these studies had small sample sizes but are consistent with the current finding of lower pCR rates in black women. The one exception was the study by Chavez-MacGregor et al 13 that found equal rates of pCR among black and white patients for HER2-positive tumors. However, this study reviewed cases from 1994 to 2008, and the majority were likely not treated with anti-HER2-targeted agents, making the results not directly comparable to current treatment in 2010 and 2011 (Table 5) .
Why non-Hispanic black women experienced the lowest rates of pCR after neoadjuvant chemotherapy in this large populationbased study is unclear. This finding persisted even after controlling for stage at presentation, age, molecular and other biologic tumor factors, comorbidity, and a host of socioeconomic factors. Of note, many factors are not captured in the NCDB database and therefore cannot be taken into account. One hypothesis is that the lower pCR rate reflects undertreatment. Women who were unable to complete chemotherapy or had dose reduction, treatment delays, or lessaggressive chemotherapy regimens would be less likely to have a pCR. The current data on delay to treatment in this group would support this theory. Furthermore, randomized trials and large institutional series also did not identify race as a predictor of pCR, suggesting that the effect may be due to variations in treatment. Several studies compared outcomes of triple-negative breast cancer between African American and white women, and most showed shorter survival and worse outcomes, 16 although others found no difference.
17 Another possibility is that unexplained inherent biologic differences exist in the breast cancers seen in non-Hispanic black women. The germline genomic diversity of African and African American women is vastly greater than that of white women and might explain the observed phenotypic differences. An overview of Southwest Oncology Group trials showed that even when carefully stage-matched patients were treated with the same chemotherapy regimens under controlled conditions, black women with breast cancer had worse survival than white women on the same trials. 18 This suggests possible differences in chemosensitivity. Furthermore, the drugs currently used for chemotherapy were selected based on trials that involved predominately white women. Data also have shown a differential response to neoadjuvant chemotherapy among seven molecular subtypes of triple-negative breast cancer. 19 Therefore, black women not only may have an increased incidence of triple-negative cancer but also may have a different triple-negative breast cancer subtype distribution, which leads to differences in chemosensitivity. Whether this poor response is related to social factors that contribute to undertreatment or biologic differences is an important question that merits further study.
Determining the mechanism of lower pCR rates among black women to neoadjuvant chemotherapy is likely to become more important in the future. The extent of the residual cancer burden after neoadjuvant chemotherapy carries strong prognostic information. 20 Patients who achieve pCR (ypT0/ypN0) or have minimal residual cancer burden have excellent survival regardless of disease subtype, whereas those with residual invasive disease (RD) have variable prognosis that is influenced by disease subtype and extent of RD. Patients with triple-negative or HER2-positive breast cancer who have extensive RD after neoadjuvant chemotherapy have a particularly poor prognosis. Until recently, no adjuvant treatment options existed for these patients. However, at least four randomized clinical trials are ongoing or planned to test the efficacy of novel adjuvant treatment strategies in this clinical setting, including trastuzumab emtansine (NCT01196052), olaparib (NCT02032823), carboplatin (EA 1131A), and pembrolizumab (SWOG S1418). If these trials show positive results, the treatment paradigm for these molecular subtypes will fundamentally change; neoadjuvant chemotherapy could be established as the most logical initial therapy to use pCR as an important biologic early surrogate marker to determine who needs subsequent adjuvant therapy.
In conclusion, we found that chemotherapy in general and neoadjuvant chemotherapy in particular are given more frequently to non-Hispanic black, Hispanic, and Asian women than to nonHispanic white women and that this is largely explained by more advanced stage, higher grade tumors, and a greater proportion of triple-negative and HER2-positive tumors in these women. NonHispanic black patients have a slightly lower likelihood of pCR after neoadjuvant chemotherapy compared with white patients, a finding that is important and needs to be studied further.
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